WINSTON-SALEM, N.C., March 11, 2013 /PRNewswire/ -- Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced it will host a conference call and live audio webcast on Monday, March 18, 2013, at 9:00 a.m. EDT to provide a business update and discuss its fourth quarter and full year 2012 financial results.
To participate in the call, please dial 1-866-543-6403 (domestic) or 1-617-213-8896 (international) and reference access code 98136968. The conference call can be accessed from the Investors & News section of the Company's website or directly at http://www.media-server.com/m/p/pfbbcfmc.
A replay of the call will be available one hour after the end of the conference on March 18, 2013 until 11:59 p.m. EDT on March 25, 2013. To access the replay, please dial 1-888-286-8010 (domestic) or 1-617-801-6888 (international) and reference the access code 69683056. The archived webcast will be available for 30 days on the Company's website at www.tengion.com.
Tengion, a clinical-stage regenerative medicine company, is focused on developing its Organ Regeneration Platform™ to harness the intrinsic regenerative pathways of the body to regenerate a range of native-like organs and tissues with the goal of delaying or eliminating the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications. An initial clinical trial is ongoing for the Company's most advanced product candidate, the Neo-Urinary Conduit™, an autologous implant that is intended to catalyze regeneration of native-like urinary tissue for bladder cancer patients requiring a urinary diversion following bladder removal. The Company's lead preclinical candidate is the Neo-Kidney Augment™, which is designed to prevent or delay dialysis kidney transplantation by in
|SOURCE Tengion, Inc.|
Copyright©2012 PR Newswire.
All rights reserved